Metasedin

Methadone Hydrochloride, the active ingredient in Metasedin, is an opioid agonist presented as an oral formulation for oral use. It is employed in the management of opioid dependence and severe chronic pain, primarily in adult patients.

GNH USA supplies Metasedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metasedin, an opioid agonist, is used in conditions where mu‑opioid receptor activation is required.

- Opioid dependence: provides maintenance therapy to reduce cravings and prevent withdrawal symptoms. - Severe chronic pain: offers long‑acting analgesia when other treatments are insufficient. - Opioid withdrawal management: eases acute withdrawal signs during detoxification programs.

Metasedin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Drowsiness: sedation or fatigue. - Nausea: upset stomach or vomiting. - Sweating: excessive perspiration. - Dry mouth: reduced salivation. - Dizziness: light‑headedness or vertigo.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Cardiac arrhythmia: QT‑interval prolongation leading to irregular heart rhythm. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before prescribing Metasedin, clinicians should consider several safety measures.

- Assess cardiac history: evaluate risk of QT prolongation and monitor ECG when indicated. - Review respiratory status: avoid use in patients with severe respiratory insufficiency. - Check liver function: dose adjustments may be needed in hepatic impairment. - Evaluate concomitant CNS depressants: monitor for additive sedation. - Counsel on dependence potential: educate patients about misuse risk. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Metasedin can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase methadone plasma levels and risk of toxicity. - Concurrent use with other opioids or CNS depressants: can cause profound respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2B6 inducers (e.g., rifampicin, carbamazepine): may reduce methadone concentrations, leading to withdrawal. - QT‑prolonging agents (e.g., haloperidol, sotalol): increase risk of cardiac arrhythmias. - Alcohol: enhances sedative effects and respiratory depression.